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Introduction 
       An effective vaccine against COVID-19 is 
widely considered the most promising exit 
strategy from the gravest pandemic in over a 
century. There were over 70 candidates em-
ploying diverse technology platforms as report-
ed by the WHO in April 2020, most targeting the 
spike (S) protein/subunits of SARS-CoV-21.
Evidence for SARS-CoV-2 Antigenic Drift
 Early sequencing efforts from the epi-
center of pandemic in Wuhan, China revealed 
>99% similarity among virus isolates from an 
index cohort of patients; this supports the sin-
gle-source of origin through a zoonotic event 
(thought to be from bats via an intermedi-
ate host) followed by rapid human-to-human 
transmission2,3. However, subsequent analy-
sis of SARS-CoV-2 genomics data from around 
the world has discovered evidence of in human 
clonal evolution with concerning implications 
for ongoing vaccine development efforts. Forst-
er et al. utilized phylogenetic network analysis 
on a limited dataset from the international Glob-
al Initiative on Sharing Avian Influenza Data 
(GISAID) to discover at least three central var-
iants (A, B, C) that are distinguished by amino 
acid changes and apparently occupied unique 
geographies in early stages of the pandemic4. A 
word of caution is the appropriateness of this 
reported use of median-joining network (MJN) 
analysis and its Steinerization process to inves-
tigate the phylogenetics of a novel virus based 
on limited genomics data prone to sampling
bias5,6. As such, any inference specifically of 
SARS-CoV-2 evolutionary directionality will 
need to be tempered for now.
 In a similar vein though, Farkas et al. 
demonstrated point mutational signatures (ma-
jority missense variants) with founder patterns 
of transmission within geographical clusters, 
indicating continued evolution as the pandemic 
unfolded7. A noteworthy observation from this 
study was the higher frequency of mutations 
affecting the helicase and ORF1ab proteins of 
SARS-CoV-2 compared to structural proteins. 
This suggests the actively evolving regions of 
the virus genome predominantly encode the 
non-structural proteins, a notion that has more 
implications for continuous design of RT-qPCR 
primer sets for diagnosis.
 However, a recent preprint of a larger 
analysis from an international collaboration 
further suggests positive selection of S mutant 
forms of the virus8. In particular, the G clade 
harboring the D614G mutation of S protein is 
seemingly increasing in frequency across geo-
graphical regions. While claims of higher trans-
missibility need functional validation, it has 
evidently become the dominant form in much 
of Europe after introduction in early February 
2020.
Implications for Investigational Vaccine 
Candidates
 A case in point is the Phase I/II clinical 
trial by University of Oxford with the candidate 
vaccine ChAdOx1 nCoV-19 under
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investigation compared to the approved menin-
gococcal vaccine MenACWY as a control (Clin-
icalTrials.gov Identifier: NCT04324606). This 
particular immunogen utilizes a well-studied, 
relatively safe chimpanzee attenuated adenovi-
rus vector (ChAdOx1) displaying the S protein 
on its surface. The vaccine construct may gener-
ate high cellular and humoral immune respons-
es against the S protein in a vaccinated individ-
ual, thus potentially conferring immunity to 
COVID-19. However, sequence for this epitope 
just like most other immunogens is based on 
the index variant ‘WH-Human1’ genome report-
ed from Wuhan, China. Therefore, it may not be 
assumed antibodies thus generated will have 
cross-neutralizing capabilities against these 
new mutants reported by Korber et al.
 Indeed, published data suggest that con-
valescent-phase plasma from most patients 
recovered from COVID-19 do not contain high 
levels of receptor binding domain (RBD)-spe-
cific antibodies9. With only a minority (1%) 
of convalescent individuals mounting highly 
neutralizing titers above 1:5,000 in the study 
by Robbiani et al., this can leave the majority 
naïve or partially immune against SARS-CoV-2 
if non-specific S protein constructs are em-
ployed for vaccination. In fact, this polyclonal 
nature of the host antibody response may in 
part explain the wide clinical spectrum of dis-
ease from asymptomatic to fatal presentations 
that have characterized COVID-19. Farrera et al. 
in a preprint also demonstrate the importance 
of specific antibodies against immunodominant 
linear epitopes corresponding to key proteo-
lytic sites responsible for ‘priming the spike’ in 
convalescent patients10. Intriguingly, the bot-
tom part of the coronavirus S protein facilitat-
ing cellular fusion as opposed to the top part, 
the latter having received the bulk of attention 
as an antibody target, can be a more promising 
target for antibody-dependent neutralization.
 So can antigenic drift of SARS-CoV-2 
spike protein jeopardize current vaccine de-
velopment? While some of these observations 
are preliminary requiring validation, concerns 
should be raised now for early modification if 
feasible of current COVID-19 vaccine trials such 
as the Oxford initiative to address evolutionary 
transitions of SARS-CoV-2. Vaccine
development is already fraught with attrition 
rates of >90%1; as such, ongoing reconstitu-
tion of vaccine constructs may be imperative 
to both reflect the prevalence of emerging viral 
mutants and avert ultimate clinical failure. The 
optimal strategy may be design and/or re-de-
sign of immunogens regardless of the platform 
utilized to elicit neutralizing antibodies against 
specific epitopes (tentatively identified) of the 
RBD, thereby enhancing the quality and dura-
tion of the host immune response.
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